Free Trial
→ GENIUS Act: Cancel Your Money? (From Priority Gold) (Ad) Free DYN Stock Alerts

Dyne Therapeutics (DYN) Financials

Dyne Therapeutics logo
$11.05 -0.14 (-1.28%)
As of 11:18 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Dyne Therapeutics

Annual Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Total Pre-Tax Income 		-15 -59 -149 -168 -236 -317
Total Operating Income		 -14 -59 -150 -171 -242 -344
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 59 150 171 242 344
Selling, General & Admin Expense		 2.79 13 29 28 31 62
Research & Development Expense		 11 45 121 143 211 281
Total Other Income / (Expense), net		 -1.03 0.11 0.73 2.86 6.23 26
Interest & Investment Income		 0.29 0.06 0.74 2.92 7.64 27
Other Income / (Expense), net		 -1.32 0.45 -0.01 -0.05 -1.42 -0.45
Basic Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Basic Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Diluted Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Weighted Average Basic & Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M

Quarterly Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -38 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Consolidated Net Income / (Loss)		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Net Income / (Loss) Continuing Operations		 -40 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Total Pre-Tax Income 		-39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Total Operating Income		 -40 -45 -67 -62 -68 -69 -72 -106 -97 -122 -116
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 40 45 67 62 68 69 72 106 97 122 116
Selling, General & Admin Expense		 6.96 7.93 7.61 7.02 8.84 25 9.70 13 15 16 17
Research & Development Expense		 33 38 59 55 59 45 62 93 82 106 99
Total Other Income / (Expense), net		 1.09 1.28 1.83 2.06 1.05 3.51 6.86 8.53 7.57 7.01 4.93
Interest Expense		 - - - - - - 0.00 - - - 0.09
Interest & Investment Income		 1.34 1.49 2.21 2.19 1.75 3.00 7.05 9.28 7.59 7.10 6.63
Other Income / (Expense), net		 -0.26 -0.22 -0.37 -0.13 -0.70 0.51 -0.19 -0.74 -0.03 -0.09 -1.60
Basic Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Weighted Average Basic Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Diluted Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Weighted Average Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Weighted Average Basic & Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M

Annual Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 6.51 288 -100 -29 -51 313
Net Cash From Operating Activities		 -12 -47 -120 -154 -188 -292
Net Cash From Continuing Operating Activities		 -12 -47 -120 -154 -188 -292
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Depreciation Expense		 0.27 0.70 1.09 1.68 1.67 1.67
Amortization Expense		 0.00 0.08 2.58 1.28 -1.10 -3.60
Non-Cash Adjustments To Reconcile Net Income		 1.35 6.14 14 17 21 46
Changes in Operating Assets and Liabilities, net		 1.41 5.11 12 -5.38 26 -19
Net Cash From Investing Activities		 -1.65 -46 -138 87 83 -204
Net Cash From Continuing Investing Activities		 -1.65 -46 -138 87 83 -204
Purchase of Property, Plant & Equipment		 -1.65 -1.16 -3.62 -3.07 -0.73 -2.38
Purchase of Investments		 0.00 -45 -237 -121 -44 -317
Sale and/or Maturity of Investments		 - 0.00 102 211 128 116
Net Cash From Financing Activities		 20 381 158 37 54 810
Net Cash From Continuing Financing Activities		 20 381 158 37 54 810
Issuance of Common Equity		 0.00 246 157 37 52 773
Other Financing Activities, net		 0.00 -0.42 0.58 0.53 1.95 37

Quarterly Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 27 8.97 -14 -37 -8.66 150 336 -76 -97 37 13
Net Cash From Operating Activities		 -29 -47 -56 -51 -35 -79 -55 -75 -84 -106 -95
Net Cash From Continuing Operating Activities		 -29 -47 -56 -51 -35 -78 -55 -75 -84 -106 -95
Net Income / (Loss) Continuing Operations		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Consolidated Net Income / (Loss)		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Depreciation Expense		 0.40 0.41 0.43 0.43 0.40 0.39 0.40 0.44 0.45 0.50 0.50
Amortization Expense		 0.03 -0.18 -0.36 -0.37 -0.19 - -1.27 -0.98 -0.84 -0.62 -0.46
Non-Cash Adjustments To Reconcile Net Income		 4.05 4.95 4.99 5.04 5.90 20 6.86 8.88 11 13 10
Changes in Operating Assets and Liabilities, net		 5.16 -7.92 4.20 4.50 26 -33 4.24 14 -5.09 -3.60 5.64
Net Cash From Investing Activities		 19 27 17 13 26 -180 11 -19 -16 1.46 6.77
Net Cash From Continuing Investing Activities		 19 27 17 13 26 -182 11 -19 -16 1.46 6.77
Purchase of Property, Plant & Equipment		 -0.52 -0.23 -0.25 -0.17 -0.08 -0.19 -0.86 -0.25 -1.08 -0.98 -0.06
Purchase of Investments		 -26 -17 -18 -9.58 - -181 -26 -57 -53 -66 -41
Sale and/or Maturity of Investments		 46 44 35 23 26 0.00 38 38 38 68 48
Net Cash From Financing Activities		 37 29 25 0.45 0.15 408 380 18 3.64 141 101
Net Cash From Continuing Financing Activities		 37 29 25 0.45 0.15 408 380 18 3.64 141 101
Other Financing Activities, net		 0.34 0.59 0.76 0.45 0.15 11 4.28 18 3.64 0.59 1.97

Annual Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 16 353 426 306 165 691
Total Current Assets		 15 349 382 266 129 659
Cash & Equivalents		 15 301 201 172 122 435
Short-Term Investments		 0.00 44 176 84 1.47 207
Prepaid Expenses		 0.13 3.77 5.82 9.58 6.28 17
Plant, Property, & Equipment, net		 1.49 1.95 4.68 5.95 4.78 5.40
Total Noncurrent Assets		 0.19 2.30 39 35 31 27
Other Noncurrent Operating Assets		 0.19 2.30 39 35 31 27
Total Liabilities & Shareholders' Equity		 16 353 426 306 165 691
Total Liabilities		 2.40 11 57 54 74 61
Total Current Liabilities		 2.36 11 29 28 51 42
Accounts Payable		 1.26 3.44 4.03 5.26 23 6.56
Accrued Expenses		 1.10 7.53 21 18 23 31
Other Current Liabilities		 - 0.00 3.89 4.61 4.72 4.85
Total Noncurrent Liabilities		 0.04 0.00 29 26 23 19
Long-Term Debt		 - - - - - 0.00
Other Noncurrent Operating Liabilities		 - 0.00 29 26 23 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 342 368 252 91 630
Total Preferred & Common Equity		 14 342 368 252 91 630
Preferred Stock		 27 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 342 368 252 91 630
Common Stock		 6.35 422 597 650 724 1,580
Retained Earnings		 -20 -79 -228 -397 -633 -950
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.27 -0.57 0.00 0.01

Quarterly Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets		 340 289 251 205 522 826 769 721 729
Total Current Assets		 298 249 213 168 488 792 736 690 698
Cash & Equivalents		 136 181 168 130 272 608 532 472 485
Short-Term Investments		 156 57 40 28 182 171 192 205 199
Prepaid Expenses		 6.10 11 5.44 10 35 13 13 12 14
Plant, Property, & Equipment, net		 5.48 5.57 5.36 5.11 4.58 5.02 4.90 5.75 5.68
Total Noncurrent Assets		 37 34 33 32 30 29 28 26 23
Other Noncurrent Operating Assets		 37 34 33 32 30 29 28 26 23
Total Liabilities & Shareholders' Equity		 340 289 251 205 522 826 769 721 729
Total Liabilities		 53 47 45 53 44 51 63 52 158
Total Current Liabilities		 26 22 20 30 22 30 43 34 41
Accounts Payable		 6.97 8.77 2.72 3.55 7.21 1.89 6.16 7.02 14
Accrued Expenses		 13 8.17 13 21 10 23 32 22 22
Other Current Liabilities		 5.49 4.64 4.71 4.71 4.76 4.78 4.81 5.11 5.00
Total Noncurrent Liabilities		 27 25 24 24 22 21 20 18 116
Long-Term Debt		 - - - - - - - - 99
Other Noncurrent Operating Liabilities		 27 25 - - 22 - 20 - 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 287 242 207 152 478 775 706 669 571
Total Preferred & Common Equity		 287 242 207 152 478 775 706 669 571
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 287 242 207 152 478 775 706 669 571
Common Stock		 605 683 713 718 1,176 1,539 1,565 1,734 1,747
Retained Earnings		 -316 -441 -506 -566 -698 -763 -860 -1,065 -1,176
Accumulated Other Comprehensive Income / (Loss)		 -1.16 -0.20 -0.06 -0.01 -0.13 -0.24 0.48 0.24 0.25

Annual Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -285.95% -154.90% -14.82% -44.60% -42.49%
EBIT Growth		 0.00% -284.16% -157.80% -13.99% -42.43% -41.37%
NOPAT Growth		 0.00% -324.18% -155.81% -13.96% -41.65% -42.01%
Net Income Growth		 0.00% -300.01% -151.18% -12.60% -40.36% -34.54%
EPS Growth		 0.00% 32.07% 29.06% -10.24% -22.29% 14.68%
Operating Cash Flow Growth		 0.00% -293.00% -157.08% -28.51% -22.46% -55.38%
Free Cash Flow Firm Growth		 0.00% 0.00% -157.33% -24.91% -13.63% -84.01%
Invested Capital Growth		 0.00% -394.46% -184.15% 56.44% -771.93% 60.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -18.25% 0.00% -13.14% -9.26%
EBIT Q/Q Growth		 0.00% 0.00% -18.45% 0.00% -12.98% -9.11%
NOPAT Q/Q Growth		 0.00% 0.00% -18.44% 0.00% -12.83% -9.36%
Net Income Q/Q Growth		 0.00% 0.00% -18.34% 0.00% -13.36% -7.78%
EPS Q/Q Growth		 0.00% 0.00% -1,727.78% 0.00% -10.34% 5.60%
Operating Cash Flow Q/Q Growth		 0.00% -52.56% -7.20% 0.00% -3.19% -20.30%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1,986.84% 15.84% -41.16%
Invested Capital Q/Q Growth		 0.00% 0.00% -227.01% 0.00% -279.41% 31.45%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 101.54% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.09% 100.58% 99.51% 98.29% 96.86% 92.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -105.86% -33.35% -42.02% -54.18% -137.31% -88.03%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 101.01% -30.79% -42.02% -54.18% -137.31% -88.03%
Return on Equity Simple (ROE_SIMPLE)		 -105.86% -17.36% -40.55% -66.61% -258.44% -50.40%
Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.41% -10.21% -12.27% -15.31% -35.04% -20.04%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.42% -185.68% -38.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -58 -150 -171 -244 -344
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -57 -146 -168 -243 -346
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Tangible Book Value (P/TBV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.01 -1.02 -1.02 -1.10 -1.06
Leverage Ratio		 1.17 1.04 1.10 1.18 1.37 1.19
Compound Leverage Factor		 1.15 1.04 1.09 1.16 1.33 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 195.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -95.42% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 54.38 52.50 5.48 3.95 -3.03 20.93
Noncontrolling Interest Sharing Ratio		 195.42% 7.70% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.26 31.83 13.31 9.46 2.53 15.60
Quick Ratio		 6.21 31.49 13.11 9.11 2.41 15.20
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -100 -124 -141 -260
Operating Cash Flow to CapEx		 -718.52% -4,005.86% -3,304.67% -5,009.62% -25,810.43% -12,305.09%
Free Cash Flow to Firm to Interest Expense		 0.00 -97.73 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -117.44 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -120.38 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.60 -2.95 -8.37 -3.65 -32 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.35 -5.43 4.73 -28 19
Enterprise Value (EV)		 246 609 236 344 693 1,755
Market Capitalization		 233 954 613 600 816 2,398
Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Tangible Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Total Capital		 14 342 368 252 91 630
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -345 -377 -256 -123 -642
Capital Expenditures (CapEx)		 1.65 1.16 3.62 3.07 0.73 2.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.23 -7.19 -23 -19 -45 -25
Debt-free Net Working Capital (DFNWC)		 12 338 354 238 78 617
Net Working Capital (NWC)		 12 338 354 238 78 617
Net Nonoperating Expense (NNE)		 5.18 18 44 48 66 77
Net Nonoperating Obligations (NNO)		 -15 -345 -377 -256 -123 -642
Total Depreciation and Amortization (D&A)		 0.27 0.78 3.67 2.96 0.57 -1.93
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.46M 51.64M 56.34M 59.68M 94.14M
Adjusted Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 51.46M 51.64M 51.98M 59.68M 94.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.40M 50.90M 51.98M 59.68M 94.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 -146.96 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -103.67 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -149.89 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -106.60 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -31.53% -29.22% -49.64% -70.59% -50.20% -8.93% -71.56% -43.02% -79.56% -63.54%
EBIT Growth		 0.00% -28.38% -27.23% -47.56% -69.28% -50.29% -7.52% -70.52% -42.03% -78.38% -62.69%
NOPAT Growth		 0.00% -27.05% -26.50% -47.29% -68.61% -52.11% -7.83% -69.67% -43.46% -76.95% -60.91%
Net Income Growth		 0.00% -24.18% -24.09% -45.49% -71.63% -48.57% -0.31% -61.31% -34.37% -75.72% -70.28%
EPS Growth		 0.00% -13.04% -6.93% -23.75% -50.68% -3.85% 35.19% 3.03% 18.18% -29.63% -38.57%
Operating Cash Flow Growth		 0.00% 7.55% -80.02% -18.22% -19.92% -67.43% 1.39% -47.48% -140.92% -34.83% -72.60%
Free Cash Flow Firm Growth		 -704.89% 48.50% -395.04% -166.58% 41.44% -211.13% 41.04% 37.87% -354.44% -2.40% -7.66%
Invested Capital Growth		 56.44% -72.02% 591.04% 0.00% -771.93% 558.11% -26.31% -202.28% 60.92% -60.42% -193.54%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 4.04% -13.70% -47.51% 7.02% -9.39% -0.12% -6.16% -46.44% 8.81% -25.69% 4.26%
EBIT Q/Q Growth		 4.46% -13.07% -46.91% 7.02% -9.60% -0.38% -5.10% -47.46% 8.71% -26.07% 4.14%
NOPAT Q/Q Growth		 5.05% -13.25% -46.79% 6.69% -8.70% -2.17% -4.06% -46.83% 8.09% -26.02% 5.38%
Net Income Q/Q Growth		 6.18% -13.80% -46.88% 7.23% -10.68% 1.48% 0.83% -49.19% 7.81% -28.83% 3.90%
EPS Q/Q Growth		 8.75% -6.85% -38.46% 8.33% -11.11% 26.36% 13.58% -37.14% 6.25% -16.67% 7.62%
Operating Cash Flow Q/Q Growth		 31.80% -60.69% -18.62% 9.06% 30.82% -124.35% 30.14% -36.02% -13.01% -25.56% 10.57%
Free Cash Flow Firm Q/Q Growth		 -42.71% 32.25% -237.06% 18.20% 68.65% -259.97% 36.12% 13.80% -129.28% 18.89% 32.84%
Invested Capital Q/Q Growth		 0.00% 202.08% 530.16% -24.45% -279.41% 177.05% -29.44% -204.86% 31.45% 178.04% -266.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.41% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.68% 96.73% 96.71% 96.49% 97.44% 95.63% 90.23% 91.28% 92.18% 94.20% 94.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32%
Cash Return on Invested Capital (CROIC)		 0.00% -1,372.22% -700.91% -1,894.77% 0.00% -1,465.59% -900.80% 0.00% 0.00% -1,538.60% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -73.04% -91.50% -136.89% 0.00% -53.84% -33.23% -41.74% 0.00% -54.88% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -32 -47 -44 -47 -48 -50 -74 -68 -86 -81
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.39% -4.40% -7.65% -24.75% -10.16% -4.98% -3.13% -5.40% -5.64% -5.34% -4.43%
Return On Investment Capital (ROIC_SIMPLE)		 -11.14% - - - -51.90% -10.13% - - -10.79% -12.47% -12.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -40 -46 -67 -62 -68 -69 -72 -106 -97 -122 -117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -45 -67 -62 -68 -68 -73 -107 -98 -123 -117
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89
Price to Tangible Book Value (P/TBV)		 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 110.31 20.14 23.26 0.00 76.43 134.50 0.00 0.00 54.02 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17
Long-Term Debt to Equity		 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17
Financial Leverage		 -1.02 -0.97 -0.96 -0.88 -1.10 -0.96 -0.96 -1.00 -1.06 -0.97 -1.00
Leverage Ratio		 1.18 1.17 1.20 1.35 1.37 1.13 1.10 1.14 1.19 1.08 1.15
Compound Leverage Factor		 1.14 1.13 1.16 1.30 1.34 1.08 0.99 1.04 1.09 1.02 1.09
Debt to Total Capital		 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 89.48% 86.61% 100.00% 100.00% 97.37% 100.00% 100.00% 97.35% 85.26%
Debt to EBITDA		 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22
Net Debt to EBITDA		 0.00 0.00 0.94 0.63 0.00 0.00 2.78 0.00 0.00 1.66 1.32
Long-Term Debt to EBITDA		 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22
Debt to NOPAT		 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32
Net Debt to NOPAT		 0.00 0.00 1.35 0.89 0.00 0.00 3.99 0.00 0.00 2.37 1.90
Long-Term Debt to NOPAT		 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32
Altman Z-Score		 5.35 6.62 6.06 2.11 0.48 30.33 36.03 33.24 22.11 12.09 2.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.46 11.54 10.54 5.67 2.53 21.83 26.63 17.02 15.60 20.35 16.83
Quick Ratio		 9.11 11.03 10.27 5.32 2.41 20.28 26.18 16.73 15.20 20.00 16.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -33 -22 -75 -61 -19 -69 -44 -38 -87 -71 -48
Operating Cash Flow to CapEx		 -5,624.66% -20,394.78% -22,256.80% -30,300.60% -42,690.24% -41,118.85% -6,402.33% -29,497.63% -7,845.12% -10,794.39% -157,838.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -506.23
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,007.48
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,008.12
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.65 3.72 23 18 -32 25 17 -18 -12 9.70 -16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.73 -9.59 28 18 -28 21 -6.17 -36 19 -15 -33
Enterprise Value (EV)		 344 411 473 412 693 1,873 2,326 2,883 1,755 524 497
Market Capitalization		 600 649 656 547 816 2,327 3,084 3,606 2,398 1,183 1,082
Book Value per Share		 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03
Tangible Book Value per Share		 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03
Total Capital		 252 242 231 176 91 478 796 706 630 687 670
Total Debt		 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00 18 99
Total Long-Term Debt		 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00 18 99
Net Debt		 -256 -238 -183 -134 -123 -454 -758 -724 -642 -659 -585
Capital Expenditures (CapEx)		 0.52 0.23 0.25 0.17 0.08 0.19 0.86 0.25 1.08 0.98 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -11 -15 -19 -45 12 -16 -31 -25 -22 -27
Debt-free Net Working Capital (DFNWC)		 238 228 193 139 78 466 763 693 617 656 656
Net Working Capital (NWC)		 238 228 193 139 78 466 763 693 617 656 656
Net Nonoperating Expense (NNE)		 11 12 18 17 19 17 15 23 22 30 30
Net Nonoperating Obligations (NNO)		 -256 -238 -183 -134 -123 -454 -758 -724 -642 -659 -588
Total Depreciation and Amortization (D&A)		 0.43 0.23 0.07 0.07 0.21 0.39 -0.87 -0.54 -0.39 -0.11 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Adjusted Weighted Average Basic Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Adjusted Diluted Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Adjusted Weighted Average Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -32 -47 -44 -47 -48 -50 -74 -68 -86 -81
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,248.81
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.27
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,249.45
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.91
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Dyne Therapeutics (NASDAQ: DYN) has maintained a consistent pattern of operating without generating revenue in recent quarters, which is typical for a clinical-stage biotech company. The company focuses heavily on research and development (R&D) expenses, which have increased steadily over the last two years, reflecting an ongoing investment into its pipeline. Below are key financial trends and highlights from the past four years through Q2 2025:

  • Strong cash and equivalents position, increasing from $130 million in Q3 2023 to $485 million by Q2 2025, providing substantial liquidity to fund operations.
  • Significant proceeds from investments sales and maturity partly offset capital expenditures and investments purchases, indicating active cash management.
  • Equity financing activities have resulted in substantial cash inflows, with large issuances of common stock contributing to growth in shareholders' equity from about $152 million in Q3 2023 to $571 million in Q2 2025.
  • Interest and investment income have provided a modest but increasing offset to operating losses, with income rising to $6.6 million in Q2 2025 from lower prior periods.
  • No revenues reported throughout all quarters analyzed, consistent with being a clinical-stage biopharma focused on pipeline development rather than commercial sales.
  • Depreciation and amortization expenses remain relatively small in absolute terms compared to R&D expenses, reflecting a mainly intangible, research-driven asset base.
  • Capital lease obligations and long-term debt appear relatively stable, indicating controlled use of borrowings for financing activities.
  • Continued net losses each quarter, with net losses increasing from approximately $39 million in Q4 2022 to over $110 million in Q2 2025, indicating rising burn rate as R&D investments grow.
  • Operating expenses, primarily driven by R&D, have risen significantly from around $40 million in Q4 2022 to nearly $116 million by Q2 2025, pressuring earnings despite the company's growth stage.
  • Negative operating cash flows have persisted every quarter, reaching nearly $95 million in Q2 2025, demonstrating ongoing reliance on financing activities to fund operations.

Overall, Dyne Therapeutics is focused heavily on developing its therapeutic pipeline, supported by strong liquidity and capital raises. The company is not yet generating revenue and continues to invest heavily in R&D, leading to growing quarterly losses and negative cash flow from operations. Retail investors should recognize the biotech development stage risks but also the healthy cash runway due to recent equity financing and investments management.

08/08/25 10:18 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Dyne Therapeutics' Financials

When does Dyne Therapeutics' financial year end?

According to the most recent income statement we have on file, Dyne Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Dyne Therapeutics' net income changed over the last 5 years?

Dyne Therapeutics' net income appears to be on an upward trend, with a most recent value of -$317.42 million in 2024, rising from -$14.86 million in 2019. The previous period was -$235.94 million in 2023. See where experts think Dyne Therapeutics is headed by visiting Dyne Therapeutics' forecast page.

What is Dyne Therapeutics' operating income?
Dyne Therapeutics' total operating income in 2024 was -$343.89 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $343.89 million
How has Dyne Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Dyne Therapeutics have?

Dyne Therapeutics' total liabilities were at $61.40 million at the end of 2024, a 16.8% decrease from 2023, and a 2,458.2% increase since 2019.

How much cash does Dyne Therapeutics have?

In the past 5 years, Dyne Therapeutics' cash and equivalents has ranged from $14.63 million in 2019 to $435.45 million in 2024, and is currently $435.45 million as of their latest financial filing in 2024.

How has Dyne Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' book value per share changed from -5.48 in 2019 to 6.19 in 2024, a change of -212.9%.


Related Companies

This page (NASDAQ:DYN) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...
Paradigm Press | Sponsored
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Crypto 101 Media | Sponsored
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsored
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...
Brownstone Research | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump c...
Weiss Ratings | Sponsored
Critical AI announcement set to ignite AI 2.0
A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...
Timothy Sykes | Sponsored
Trump’s new nightmare
According to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...
Porter & Company | Sponsored
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsored